(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 14.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Vericel's revenue in 2025 is $258,717,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2025 to be $14,140,497,670, with the lowest VCEL revenue forecast at $13,505,793,643, and the highest VCEL revenue forecast at $14,629,042,761. On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $16,763,266,658, with the lowest VCEL revenue forecast at $15,870,129,359, and the highest VCEL revenue forecast at $17,514,796,684.
In 2027, VCEL is forecast to generate $19,998,487,101 in revenue, with the lowest revenue forecast at $18,382,646,970 and the highest revenue forecast at $21,273,964,037.